Drug Trial Radar · NCT04713514
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Aug 5, 2021
Primary completion
Dec 15, 2025
Study completion Nov 9, 2026
Sponsor
- Lead sponsor
- ARCAGY/ GINECO GROUPAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- OSE Immunotherapeutics; Merck Sharp & Dohme LLC
- First posted
- Jan 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed study is an international randomized phase II, multicenter, open-label, three arms trial to assess best supportive care (BSC) vs OSE2101 and vs OSE2101 + pembrolizumab as maintenance treatment for patients with platinum sensitive relapsed ovarian cancers, previously treated with chemotherapy (regardless of the number of prior lines of platinum-based chemotherapy), bevacizumab (if eligible) and a PARP inhibitor (if eligible). Patients in Complete Response, Partial Response, or Stable Disease at the end of chemotherapy with at least 4 cycles of platinum based chemotherapy will be randomized in one of the three arms (randomization 1:1:2). They will receive one or the two study treatments or BSC until progression, or intolerance, or up to 2 years (from 1st study treatment dose).
Conditions
- Platinum-sensitive Ovarian Cancer
- Relapsed Ovarian Cancer
Interventions
OSE2101Drug
subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Pembrolizumab 25 MG/ML [Keytruda]Drug
400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: from date to randomization to date of event, assessed up to 4 years
Locations
41 sites in 3 countries. Site status is shown where the registry gives one.
UZ Leuven
Leuven, Belgium
Centre Hospitalier de l'Ardenne Vivalia
Libramont, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
ICO Paul Papin
Angers, France
Institut du Cancer Avignon-Provence
Avignon, France
Centre Hospitalier de la Côte Basque
Bayonne, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre d'Oncologie et de Radiothérapie 37
Chambray-lès-Tours, France
Centre Hospitalier de Cholet
Cholet, France
Centre Jean PERRIN
Clermont-Ferrand, France
Centre Georges François Leclerc
Dijon, France
CHU Grenoble-Alpes - Site Nord (La Tronche)
Grenoble, France
Centre Oscar Lambret
Lille, France
CHU Limoges - Dupuytren
Limoges, France
Hôpital Privé Jean Mermoz
Lyon, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
ICM - Val d'Aurelle
Montpellier, France
Hôpital Privé du Confluent
Nantes, France
Centre Antoine Lacassagne
Nice, France
Hôpital Pitié-Salpêtrière - AP-HP
Paris, France
Hôpital Cochin
Paris, France
Groupe Hospitalier Diaconesses-Croix Saint-Simon
Paris, France
Center Hospitalier de Pau
Pau, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre CARIO - HPCA
Plérin, France
Centre Eugène Marquis
Rennes, France
ICO - Centre René Gauducheau
Saint-Herblain, France
CHU de Saint-Etienne - Pôle de Cancérologie
Saint-Priest-en-Jarez, France
Centre Hospitalier Broussais
St-Malo, France
CHU Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Institut Claudius Régaud
Toulouse, France
Gustave Roussy
Villejuif, France
Universitätsklinikum Carl Gustav Carus
Dresden, Germany
Evang. Kliniken Essen-Mitte GmbH
Essen, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Universitätsmedizin Mainz
Mainz, Germany
Universitätsmedizin Mannheim GmbH
Mannheim, Germany
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.